FOR IMMEDIATE RELEASE
PROMISING CANNABIS STOCKS GAIN ATTRACTIONInvesting In The Cannabis Industry Stock Options
Projections of growth in the marijuana industry in the U.S. and Canada has generated a lot of investor interest. Companies trading in the stock exchange range from companies concentrating on specific niches, to medicinal and recreational marijuana manufacturers and distributors.
Many marijuana businesses are using the opportunity to raise capital for expansion and innovation. The SEC has asked investors to be cautious in their investments. In this article, we look at some of the most promising stock options today.
Cronos Group INC
Cronos Group (Nasdaq: CRON) is one of the medical marijuana companies that has generated a lot of attention and shows signs of growth potential. Cronos second quarter financial report revealed an increase in revenue from $600,000 for the second quarter of 2017 to $3.4 million in the second quarter of 2018.
The company is raising money to increase its manufacturing capacity. One of its investment includes a 286,000 square foot facility located in Ontario. The project is set to be the largest indoor cannabis purpose-built facility in the world. Additionally, the company has made a deal with MedMen, a top cannabis retail chain in California, to improve distribution. It is one of the cannabis businesses that is taking bold strides to enhance manufacturing, product offering, and distribution as it expands across the globe.
Tilray is another Canadian company which aims to be a global leader in the research processing, cultivation, and distribution of both medical and recreational cannabis. In 2017, Tilray registered sales of over $20 million in medical marijuana products. The company is now taking advantage of the opportunity to expand and record more profits, since Canada’s nationwide initiative to legalize the recreational use of marijuana.
Tilray was the first marijuana company to export cannabis to Europe. It has established a global presence and works with distributors in South Africa, Peru, Cyprus and the Zech Republic amongst other countries. Their stock has been volatile in the Nasdaq since July when trading started, but Tilray stocks show signs of promise as prices stabilize towards the end of 2018.
Corbus Pharmaceuticals Inc
Corbus Pharmaceuticals Inc (CRBP) specializes in developing medication to treat fibrotic and inflammatory diseases. Corbus Pharmaceuticals is known for the development of Anabasum a drug that naturally binds with CBD receptors to facilitate treatment of various conditions.
Anabasum has been on clinical trials for a while. However, in late 2017, phase two data showed positive results for the use of the drug in treating systemic sclerosis. The condition does not have a cure and there is no established therapy to manage it.
Thanks to these findings, the stocks rose by 166% within the first year. There is a concern on whether the drug will be approved as the final clinical trials are to be released. If this is the case, the company stands to receive revenues in the range of a billion dollars in the sale of the drug for managing systemic sclerosis.
Marrone Bio Innovations
Marrone Bio Innovations (Nasdaq: MBII) deals with plant health and pest management products. MBII has been developing products specifically for marijuana cultivators in states and regions where it’s legal.
MBII had been facing low returns and significant losses towards the end of 2017. However, in 2018 the stocks turned around with renewed interest from investors. Part of what improved the stocks is the company’s successful development of plant safety products that can be used by organic farmers and marijuana cultivators.
Marrone Bio Innovations has adopted processes that have made their products faster and less costly to develop. They’re also looking to diversify their portfolio plant health products. MBII has generated a lot of excitement since the beginning of 2018 and has managed to steer from a loss to inspire new investor confidence.
Zynerba Pharmaceuticals (Nasdaq: Zyne) is a specialty company that develops synthetic cannabinoid products. Zynerba is currently developing therapeutics that are in clinical trials for the treatment of osteoarthritis and refractory epilepsy.
In its fourth-quarter financial reports, the company had a loss of $8.1 million which amounted to a loss of 60 cents per share. The total annual loss was $32 million which is $2.48 per share. Even though the company has had a volatile growth, experts believe it’s still a stock option with great mid to long-term growth potential.
Cannabexchange is a media and news social platform that aims to provide cannabis enthusiast a hub for cannabis related content & features in which they can engage and conduct legal business in a safe environment. Cannabexchange is not a legal adviser nor do we present ourselves as such. All investment opportunities mentioned in this or any other press and sponsored articles is not made as legal investment advise and meant for entertainment and informational purposes only. You are recommended to do your own research and consult your own legal and financial advisers before making investment decisions.
There are a lot of opportunities being created with the new ballots recently added to the last election, and as usual, the markets will continue to follow. The more we legalize it, the more investment opportunities we'll find. I'm excited to see what will come ten to twenty years from now.